BETHESDA, Md., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided the following letter to shareholders from the Company’s President and CEO, Gene Mack:
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update
Seeking Alpha / 2 hours from now 1 Views
Comments